Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.
3.

Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.

Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.

Q J Nucl Med Mol Imaging. 2008 Mar;52(1):2-8.

4.

Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.

Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY.

J Nucl Med. 1999 Jun;40(6):986-92.

5.

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Bzorek M, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2013;8(1):e53410. doi: 10.1371/journal.pone.0053410. Epub 2013 Jan 4.

6.

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

BMC Cancer. 2013 Apr 1;13:168. doi: 10.1186/1471-2407-13-168.

7.

Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.

Kingpetch K, Pipatrattana R, Tepmongkol S, Sirisalipoch S, Chaiwatanarat T.

J Med Assoc Thai. 2011 Oct;94(10):1238-44.

PMID:
22145510
8.

Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.

Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N.

BMC Cancer. 2010 Dec 3;10:667. doi: 10.1186/1471-2407-10-667.

9.

Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.

Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR.

J Nucl Med. 2009 Jan;50(1):116-22. doi: 10.2967/jnumed.108.056077. Epub 2008 Dec 17.

10.

[Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax].

Zhang TM, Zhang LM, Liu Y, Zhang ZF, Wang CL.

Zhonghua Yi Xue Za Zhi. 2012 Nov 6;92(41):2901-4. Chinese.

PMID:
23328236
11.

Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.

Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL.

Ann Surg Oncol. 2008 Jan;15(1):286-92. Epub 2007 Sep 20.

PMID:
17882493
12.

124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.

Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mojzisik CM, Johnson MA, Knopp MV, Martin EW Jr, Sun D.

World J Surg Oncol. 2010 Aug 6;8:65. doi: 10.1186/1477-7819-8-65.

13.

Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.

Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L, Banti E, Carpi A, Muzzio P, Franchi R.

Biomed Pharmacother. 2006 Sep;60(8):409-13. Epub 2006 Aug 1. Review.

PMID:
16891093
14.

Can calcification predict 131I accumulation on metastatic lymph nodes in papillary thyroid carcinoma patients receiving 131I therapy? Comparison of CT, 131I WBS and 18F-FDG PET/CT.

Kaneko K, Abe K, Baba S, Tanabe Y, Yabuuchi H, Hatakenaka M, Sasaki M, Honda H.

Eur Radiol. 2010 Feb;20(2):477-83. doi: 10.1007/s00330-009-1557-5. Epub 2009 Sep 2.

PMID:
19727757
15.

Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice.

Lee KH, Ko BH, Paik JY, Jung KH, Choe YS, Choi Y, Kim BT.

J Nucl Med. 2005 Sep;46(9):1531-6.

17.

PET and macro- and microautoradiographic studies combined with immunohistochemistry for monitoring rat intestinal ulceration and healing processes.

Yamato M, Kataoka Y, Mizuma H, Wada Y, Watanabe Y.

J Nucl Med. 2009 Feb;50(2):266-73. doi: 10.2967/jnumed.108.057943. Epub 2009 Jan 21.

18.

Longitudinal evaluation of tumor metastasis by an FDG-microPet/microCT dual-imaging modality in a lung carcinoma-bearing mouse model.

Chang CH, Jan ML, Fan KH, Wang HE, Tsai TH, Chen CF, Fu YK, Lee TW.

Anticancer Res. 2006 Jan-Feb;26(1A):159-66.

19.

Noninvasive Evaluation of Metabolic Tumor Volume in Lewis Lung Carcinoma Tumor-Bearing C57BL/6 Mice with Micro-PET and the Radiotracers 18F-Alfatide and 18F-FDG: A Comparative Analysis.

Wei YC, Hu X, Gao Y, Fu Z, Zhao W, Yu Q, Wang S, Zhu S, Li J, Yu J, Yuan S.

PLoS One. 2015 Sep 9;10(9):e0136195. doi: 10.1371/journal.pone.0136195. eCollection 2015.

20.

[Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].

Liu X, Zhou NK, Zhang JM, Liang ZY, Zheng X.

Ai Zheng. 2006 Dec;25(12):1512-6. Chinese.

PMID:
17166377
Items per page

Supplemental Content

Write to the Help Desk